Life Sciences

California biologics company LakePharma, with operations in Hopkinton and Worcester, has announced it is making versions of purified COVID-19 proteins available to the biotech community for use in antibody and diagnostic development.

New hires and promotions at companies like AAFCPAs in Westborough, Bryley Sytems in Clinton, Concierge Physical Therapy in Sutton, Reliant Medical Group and Framingham State University.

Holliston biotechnology firm Harvard Bioscience, Inc. has developed a new technology to provide researchers with real-time access to aerosol amounts deposited inside subjects' lungs, the company said in a press release.

A test for the novel coronavirus run on the Panther system from Marlborough medical device manufacturer Hologic has received Emergency Use Authorization from the U.S. Food and Drug Administration.

The Worcester City Council's economic development committee has recommended the full council approve a $11.5-million tax break for a proposed biomanufacturing facility by WuXi Biologics.

Waters Corp., a Milford manufacturer of lab equipment, announced new pieces of equipment at sciences conference Pittcon 2020 in Chicago.

In its fourth-quarter earnings report released Wednesday, Holliston biotech Harvard Bioscience announced it has started a restructuring program expected to save about $4 million, including laying off workers and closing its facilities.

Acton manufacturer of wearable insulin management systems Insulet reported strong numbers for the fourth quarter of 2019 and for the year, but they were not up to analyst expectations and the stock slid down nearly 5% in early morning training Wednesday.

The Worcester city administration is recommending the City Council on Tuesday approve a $11.5-million tax break to benefit WuXi Biologics, a firm planning a biomanufacturing facility off Belmont Street.

Hopkinton biopharmaceutical company Spring Bank Pharmaceuticals reported increased losses in the fourth quarter, in the first report since the company announced it would cease development of a treatment for chronic hepatitis B after a patient died during a trial.